Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lots unknown but at a $45 million market cap with $28 million in current revenue it's attractive for long term value.
If they are actually successful in filing 4 ANDA's in 2022, that will be a sight to see.
It's been a long journey and still a long ways to go. As I mentioned before, I'm really hoping to see at least 2 ANDA's submitted in first half of calendar 2022. If we get that done, I'd be content.
(Very very) slow and steady wins the race here.
Revenue to market cap the stock is interesting in the .04's for long term value. $6-$7 million a Q currently with ANDA filings hopefully next year sets the stage for a great value, if you don't mind sitting on dead money for 12-24 months. (most investors wont, especially in OTC land hence the depressed PPS.)
Generics isn't a flashy business for sure. A big product or two approved would do wonders. Issue is an approval is ~18 months away. Can't see the share price going much lower unless revenues disintegrate. We'll see.
Hopefully some results soon. The .04's range is holding but who knows if we go another 6 months with no positive BE results. Hoping for 2 submissions in 2022. At this point, whatever management is hoping for just cut it in half, maybe a third to be conservative.
Not sure you can even call it an attempt.
That has been a killer. I for one thought at this point we would be nearing 10% of the market for XR. Alas, not even close.
For sure, what happened to the 10% of the 1.5 billion dollar market, What's wrong with that picture.
Why would the Nasdaq have any correlation to a penny stock? lol, I've never understood that logic.
Lannett is a disaster, probably won't be around in 5 years.
Well, we need the ER revenues to grow...and grow a ton to get us to the 10% penetration Nasrat has talked about in the past. Right now it's pathetic to be honest.
Time to show us the $ Nasrat.
No the problem is there's no interest from new buyers to purchase shares. Until the new $ flows into Elite, the share price won't rise.
Which is why I don't see the share price going up much anytime soon. We basically have a 12 month wait until substantial news, and that's being generous. Still a great level to buy at if you are patient and don't need the money right away.
Let's slow down a bit there. Small steps.
$7.1 million is a win.
$1 million operating profit
Historically the share price rises heading into the calls, then drops after. Hoping for some good comments from Nasrat coming up to bring some enthusiasm back.
Adderall market capture so far is something that needs to be brought up as well. Disappointing for sure. Perhaps people have seen what we've been able to get from Adderall so far and question what kind of market penetration we can get from the other large products we're working on.
I'm glad the lights aren't going to be shut off but we really need a turn around quick. Hoping for some good numbers and a stellar call from Nasrat.
Yes but it's not as if he owns 75% of it. Hopefully if he doesn't realize it, someone else within the company has to courage to bring it up that we need a different course.
More interaction with the investing public, letting shareholders know more of what's being worked on. It's clear that this secretive methodology that we're using isn't working and unless Nasrat has something huge he's about to drop, I don't see things turning around for awhile as it's known that the stock doesn't move up on product results and even launches. Looking at things, I don't really see much happening for the next 12 months.
And it sure looks like I'm not the only one that feels this way. We need something and we need it ASAP.
There comes a time and point when a CEO needs to realize that what he/she has been doing just hasn't been working and changes things up a bit. I really hope Nasrat is close to this realization.
Calendar
Liking what I hear.
Sequestox is dead man, been dead for years.
I bought 800k more in the past 2 months. No more $ for me until August. We'll see.
Agree completely. Watching this thing pinball from .05 to .06 is stupid. If you own it, sit back, put news alerts on from IR and don't check it. No reason to. It's not going to go up until substantial news hits.
Elite needs to show it can capture any sort of significant market share with Lannett. If they can, then yes the current $55 million market cap is severely undervalued.
Yeah, products fail all the time. You are aware of this, right?
Yeah because they had to switch industries completely when Sequestox failed. We could've very easily gone under a few years ago.
Can look at it both ways.
We both know who's right...and it feels good to be on the right side. ;)
WRONG.
wink wink.
Nobody has made one penny under Nasrat's "leadership".
I mean, within a year of him joining the stock did run from .07 to .97
;)
Chart looking good; .08's coming before you know it.
Lots of brokers allow iceberg orders for retail these days. In the order selector you just input how many shares you want to buy vs how many will show up on Level 2.
Anyone can do that, it's called an iceberg order. Not a MM.
I transferred another $5k to buy more tomorrow.
On the way back to the .09's leading up to next months annual report.
Seems like people MIGHT be catching on that the idea of the market is to buy the lows, not the highs. ;)
So who is short shares of ELTP? Retail? Hedgefunds? MM's?
It's another good step in the right direction.
They are inaccurate numbers. You can check on a handful of OTC's and it'll show crazy percentage shorting numbers. It just isn't real. No one is shorting a 5 cent stock.
Never say ever.